News Release

share on google plus
Text size
view with small font size
view with medium font size
view with large font size

Kyowa Hakko Kirin News Releases 2014

December 18, 2014
Approval for Additional Indication for Chemotherapy-Native CCR4-positive ATL of Mogamulizumab
December 18, 2014
Approval for Additional Indication of NESP® for Anemia with Myelodysplastic Syndromes in Japan
December 10, 2014
ONO PHARMACEUTICAL, Bristol-Myers Squibb and Kyowa Hakko Kirin Announce Immuno-Oncology Clinical Collaboration Studying Opdivo (nivolumab) and Mogamulizumab in Advanced Solid TumorsPDF file:New window opens(71KB)
November 27, 2014
Launch of Sustained-Duration G-CSF Product G-Lasta® in Japan
October 30, 2014
Completion of Construction for Drug Product Manufacturing Facility in the Takasaki Plant
October 28, 2014
Consolidated Financial Summary Fiscal 2014 Third QuarterPDF file:New window opens(173KB)
October 28, 2014
Appendix to the Consolidated Financial Summary Fiscal 2014 Third QuarterPDF file:New window opens(241KB)
September 30, 2014
Pfizer and Kyowa Hakko Kirin to Collaborate on Immuno-Oncology Combination StudyPDF file:New window opens(54KB)
September 26, 2014
Approval for Sustained-Duration G-CSF Product G-Lasta® in Japan
September 16, 2014
Announcement of Results from Long-Term Phase 1/2 Study of KRN23 in X-linked Hypophosphatemia in Adults
September 11, 2014
Launch of Dovobet® Ointment Topical Combination Drug for Psoriasis VulgarisPDF file:New window opens(34KB)
September 3, 2014
Launch of Redesigned Kyowa Hakko Kirin Pharma Website
August 29, 2014
Kyowa Hakko Kirin Announces Commencement of Phase 2b Clinical Study of KHK7580 in Patients with Secondary Hyperparathyroidism in Japan
August 6, 2014
ProStrakan Completes Acquisition of ArchimedesPDF file:New window opens(33KB)
August 1, 2014
Kyowa Hakko Kirin Submits Application for Approval in Japan for KW-3357
July 30, 2014
Consolidated Financial Summary Fiscal 2014 InterimPDF file:New window opens(134KB)
July 30, 2014
Appendix to the Consolidated Financial Summary Fiscal 2014 InterimPDF file:New window opens(296KB)
July 30, 2014
Results Presentation Fiscal 2014 InterimPDF file:New window opens(1,566KB)
July 30, 2014
Kyowa Hakko Kirin and AstraZeneca Partner on Immuno-Oncology Clinical StudyPDF file:New window opens(33KB)
July 30, 2014
Domestic Sales Outsourcing Agreement for Recombinant Human Antithrombin Preparation SignedPDF file:New window opens(11KB)
July 29, 2014
Announcement of Start of Phase 1 Joint Japanese-Korean Study of a Human Monoclonal Anti-FGF23 Antibody (KRN23) in X-linked Hypophosphatemic Rickets/Osteomalacia in Adults
July 24, 2014
Kyowa Hakko Kirin Announces Initiation of a Phase 2 Study of KRN23 for Pediatric X-Linked Hypophosphatemic Rickets in the US and EU
July 11, 2014
ProStrakan enters into agreement to buy ArchimedesPDF file:New window opens(39KB)
July 4, 2014
Topical Combination Drug Dovobet® Ointment Approved to Treat Psoriasis Vulgaris
July 2, 2014
Future Development Direction for Bardoxolone Methyl (RTA 402)
June 30, 2014
Reapplication Seeking Approval for Additional Indication for ATL of Mogamulizumab
June 25, 2014
Announcement of Results from a Multiple Dose Phase 1/2 Study of a Human Monoclonal Anti-FGF23 Antibody (KRN23) in X-linked Hypophosphatemia in Adults
June 20, 2014
Hisamitsu Pharmaceutical is received Approval for Additional Indication of Chronic Pain for Fentos® Tape, a Transdermal Long-Acting Pain Relief Patch
June 18, 2014
Kyowa Hakko Kirin initiates a Phase I Trial of KHK6640 for Alzheimer's Disease in Europe
May 1, 2014
Launch of a New Formulation of Topina®, an Antiepileptic Agent
April 24, 2014
Consolidated Financial Summary Fiscal 2014 First QuarterPDF file:New window opens(250KB)
April 24, 2014
Appendix to the Consolidated Financial Summary Fiscal 2014 First QuarterPDF file:New window opens(261KB)
April 17, 2014
Termination of Mogamulizumab Licensing Agreement with Amgen
April 16, 2014
Kyowa Hakko Kirin initiated a Pivotal Phase 3 Trial of Benralizumab (KHK4563) for Severe Asthma in Japan
April 8, 2014
Completion of Construction for the biopharmaceutical API manufacturing facility in the Takasaki Plant
March 31, 2014
Application Seeking Approval for Additional Indication of NESP® for Anemia with Myelodysplastic Syndrome in Japan
March 28, 2014
Matters concerning controlling shareholdersPDF file:New window opens(23KB)
March 25, 2014
Kyowa Hakko Kirin Submits Application for Approval of REGPARA® Tablets 12.5mg in Japan
March 20, 2014
Notice regarding allotment of stock acquisition rights(stock compensation-type stock options)PDF file:New window opens(23KB)
March 19, 2014
New window opensLonza and BioWa Sign POTELLIGENT® CHOK1SV Cell Line Technology Licensing Agreement with arGEN-XPDF file:New window opens(155KB)
March 17, 2014
Approval for Additional Indication for PTCL and CTCL of Mogamulizumab
March 10, 2014
Correction of one section of the Consolidated Financial Summary Fiscal 2013PDF file:New window opens(37KB)
February 28, 2014
Construction to Begin on New IK8 Research Building at Fuji Research Park
February 26, 2014
Correction of one section of the Consolidated Financial Summary Fiscal 2013PDF file:New window opens(46KB)
February 21, 2014
Approval for Additional Indication of REGPARA® Tablets 25mg and 75mg
February 19, 2014
Position and policies concerning the reduction of the minimum investment unitPDF file:New window opens(10KB)
February 19, 2014
Notice regarding stock acquisition rights for the purpose of granting stock compensation-type stock optionsPDF file:New window opens(18KB)
February 10, 2014
Change to Supplemental Application Seeking Approval of Additional Indication for Mogamulizumab
February 4, 2014
Kyowa Hakko Kirin Announces Commencement of Phase 3 Clinical Study of ARQ 197 (Tivantinib) in Patients with Hepatocellular Carcinoma in Japan
February 4, 2014
Correction of figure included in the Kyowa Hakko Kirin Presentation Materials for Fiscal year ended December 2013PDF file:New window opens(85KB)
January 31, 2014
Kyowa Hakko Kirin Fiscal 2013 Results: Strong domestic pharmaceutical sales, forex, and extraordinary gains offset challenging operating environmentPDF file:New window opens(201KB)
January 31, 2014
Consolidated Financial Summary Fiscal 2013PDF file:New window opens(206KB)
January 31, 2014
Appendix to the Fiscal 2013 Consolidated Financial StatementsPDF file:New window opens(234KB)
January 31, 2014
Fiscal 2013 Results PresentationPDF file:New window opens(3,344KB)
January 31, 2014
Kyowa Hakko Kirin to Consolidate and Reorganize Research and Development DivisionsPDF file:New window opens(82KB)
January 23, 2014
Launch of Long-Acting Erythropoiesis-Stimulating Agent NESP® Injection 5 μg Plastic Syringe in Japan
January 20, 2014
Notice of revisions to the Appendix to the Fiscal 2013 Third Quarter Consolidated Financial StatementsPDF file:New window opens(704KB)
January 17, 2014
Approval of Fine Granules of Topina®, an Antiepileptic Agent
January 15, 2014
Addition of Japanese Sites for Pivotal Phase 3 Trial of Mogamulizumab (KW-0761) in Patients with Cutaneous T-Cell Lymphoma

Get Adobe® Reader®You need Adobe® Reader® to view these documents.
Download Adobe® Reader® of Adobe Systems here.



To Page Top